As a part of its Texas Startup Manifesto, Austin-based Capital Factory came into town to talk about the Houston's ecosystem and advice for tech startups looking to do business in town. Natalie Harms/InnovationMap

Throughout the year, Austin-based Capital Factory loads up a bus and takes startup founders and tech entrepreneurs around the Lone Star State in order to better connect the dots of innovation within Texas' major metros. The Texas Startup Manifesto bus recently put it in park outside Station Houston and hosted a tech-focused panel at Accenture's innovation hub.

The panel, which was hosted by two deep tech startup founders, asked some important questions about Houston's ecosystem and startup needs to three experts. Trevor Best of Syzygy Plasmontics and Diana Liu of Arix Technologies represented the startups, while Allison Sawyer of League of Worthwhile Ventures, Mark Volchec of Las Olas VC, and Brian Richards of Accenture fielded their questions.

The panel started out with the state of Houston's innovation ecosystem — which, of course, was the whole point of the one-day field trip to the Bayou City. The panelists seemed to agree that Houston has things it needs to improve on, but the point is not to try to copy any other market.

"We can't try to be Silicon Valley. We're just simply not," Richards says. "What we have to focus on is what our strengths are."

For instance, Houston has a lot of money within the city, but that hasn't yet translated to a large amount of investments in startups. Even if the city found $1 billion to start investing in companies, Richards says that wouldn't solve everything instantly. Houston has to be able work on the ecosystem as a whole, not just one thing in particular.

"We have so many problems to solve, and we have to solve them in parallel," Richards says. "We have to fix them all at once."

The city's ecosystem aside, the panel weighed in on some of their own advice for tech startups making waves in Houston.

Hire a business-minded leader, like, yesterday.

One of the most crucial aspect for any startup is the team behind the product, and having a diversity of expertise on that team is especially in tech startups, which are usually instigated by a tech-focused founder.

"I think it's really important to have a balanced founding team," Volchec says. "If everyone is tech, I think it's really difficult."

As a venture capitalist and former founder himself, Volchec's biggest critique is that, startups and founders don't start sales early enough. Volchec says he once signed a deal with a company before they even had a product let alone revenue. The key distinguisher for him was that the company already had contracts in place from customers.

Having that person to sell the company is so important, and you need a business-focused person at the helm to do so. For most companies, that's not the tech-minded founder.

"If you're the scientist, why do you even want to be the CEO?" Volchec asks. "The CEO's job is to be out there and selling — to investors, to clients, to employees."

According to the panelists, sooner is better for making that hire.

"if you don't hire a CEO, and you raise enough money, someone will hire a CEO for you, and you might not like that CEO," Volchec says.

Have a free discovery.

In particular, B-to-B companies should have a free trial, so to speak, for their product. It's Sawyer's pet peeve, she says, when startups charge for the discover process. It's strategic to give access to some people within the company your startup is trying to sell to, that way they get hooked and want to get more access for their whole team.

It does make the process a little more challenging, Sawyer says, since it requires a little more upfront funds.

"You do have to raise a little bit more money, but you do get to scale a lot faster," she says.

Corporate venture groups can be more than just investment. 

When looking to scale your product into bigger corporations, a way in is through corporate venturing groups, according to the panelists, even if money isn't the right fit. You're more likely to get a meeting with a venture arm than with the company itself.

"I never took corporate venture money, because they were a little too slow and it was a lot of extra accounting work, Sawyer says. "But I loved working with corporate venture when it comes to pilots. I think they are an underused resource for startups."

It also helps that more and more companies are devoting resources to these groups.

"I'm seeing corporate venture groups all over the place," Sawyer says. "Even if you're not taking their money, they will get you in the door for a pilot."

Overall, big companies are more keen to work with startups of late, says Richards, who hosts C-level execs from big companies on a daily basis in Accenture's Innovation Hub.

"I've never seen [corporations] more motivated than they are right now to be able to think differently on how they are able to engage Houston," he says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”